I dont think it was to incorporate Si3N4 into US Spine IP as much as to have a more complete spinal portfolio. CTL already brings a more complete portfolio to the table so it doesnt need US Spine IP as far as I can tell.
However what youve highlighted seems to match what Sonny was saying during the CC about their struggles to sell without a complete portfolio. This is all part of understanding the full picture, thanks.
Thank you for this new insight. Very interesting. Perhaps this explains the relatively low sale price of the spinal portfolio. This is not all bad; however, as it definitely simplifies any efforts to sell the remaining IP and manufacturing capabilities/deals. OMID
News 
Market Data 
Discover 
